Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Price Target from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $7.30.

A number of research analysts recently commented on ESPR shares. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective for the company.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $2.24 on Friday. The company’s 50-day moving average is $2.47 and its two-hundred day moving average is $2.18. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94. The firm has a market capitalization of $441.36 million, a price-to-earnings ratio of -3.50 and a beta of 1.03.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Bank of New York Mellon Corp grew its stake in shares of Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Esperion Therapeutics by 6,560.6% in the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock valued at $560,000 after acquiring an additional 248,254 shares during the last quarter. National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares in the last quarter. American Century Companies Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $50,000. Finally, BOKF NA acquired a new position in Esperion Therapeutics in the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.